AtriCure, Inc. Research and Development Asset Acquired Other than Through Business Combination, Written-off
AtriCure, Inc. (ATRC) reported Research and Development Asset Acquired Other than Through Business Combination, Written-off of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-27.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff · last filed 2026-07-27
- AtriCure, Inc. research and development asset acquired other than through business combination, written-off for the quarter ending 2025-12-31 was $1.00M, a 91.67% decline year-over-year.
- AtriCure, Inc. research and development asset acquired other than through business combination, written-off for the quarter ending 2025-09-30 was $0.00.
- AtriCure, Inc. research and development asset acquired other than through business combination, written-off for the quarter ending 2024-12-31 was $12.00M.
- AtriCure, Inc. research and development asset acquired other than through business combination, written-off for the quarter ending 2024-09-30 was $0.00.
- AtriCure, Inc. research and development asset acquired other than through business combination, written-off for fiscal 2025 was $6.00M, a 50.00% decline from fiscal 2024.
- AtriCure, Inc. research and development asset acquired other than through business combination, written-off for fiscal 2024 was $12.00M.
- AtriCure, Inc. research and development asset acquired other than through business combination, written-off for fiscal 2023 was $0.00.
- AtriCure, Inc. research and development asset acquired other than through business combination, written-off for fiscal 2022 was $0.00.
| Period end | Research and Development Asset Acquired Other than Through Business Combination, Written-off 3 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 6 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 9 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-07-27 | |||
| 2025-12-31 | $1.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $1.00M derived: sum of 2 quarters · filed 2026-02-19 | $6.00M 10-K · filed 2026-02-19 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $5.00M 10-Q · filed 2025-10-30 | ||
| 2025-06-30 | $5.00M 10-Q · filed 2026-07-27 | |||
| 2024-12-31 | $12.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $12.00M derived: sum of 2 quarters · filed 2026-02-19 | $12.00M 10-K · filed 2026-02-19 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $0.00 10-Q · filed 2025-10-30 | ||
| 2024-06-30 | $0.00 10-Q · filed 2025-07-30 | |||
| 2023-12-31 | $0.00 10-K · filed 2026-02-19 | |||
| 2022-12-31 | $0.00 10-K · filed 2025-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| iRhythm Holdings, Inc. (IRTC) | United States | $3.651B | -281.06 |
| PULSE BIOSCIENCES, INC. (PLSE) | United States | $3.696B | -24.47 |
| UFP TECHNOLOGIES INC (UFPT) | United States | $2.308B | 28.37 |
| ICU MEDICAL INC/DE (ICUI) | United States | $4.153B | 18.85 |
| Inspire Medical Systems, Inc. (INSP) | United States | $1.990B | 9.55 |
| Heartflow, Inc. (HTFL) | United States | $4.225B | |
| NovoCure Ltd (NVCR) | $1.886B | -11.87 | |
| LEMAITRE VASCULAR INC (LMAT) | United States | $1.848B | 33.37 |
| KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) | United States | $1.535B | -9.02 |
| Alphatec Holdings, Inc. (ATEC) | United States | $1.531B | -12.14 |